Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation
Agenus (NASDAQ: AGEN) has released findings from its national Colorectal Cancer in Focus survey, revealing critical gaps in current treatment options. The survey, conducted from October to December 2024, gathered insights from patients and healthcare providers (HCPs) about colorectal cancer (CRC) care.
Key findings show that over 50% of HCPs reported increased CRC diagnoses in adults under 50, with 82% of surveyed patients diagnosed before that age. An overwhelming 93% of HCPs believe current CRC treatments are insufficient. The survey highlighted that 61% of patients expressed interest in non-chemotherapy treatments, including immunotherapy, while 37% of HCPs identified immunotherapy as the most promising advancement in CRC treatment.
The study, conducted in partnership with the Colorectal Cancer Alliance and Fight Colorectal Cancer, emphasizes patients' prioritization of quality of life, with one-third citing minimal life impact as a top treatment priority. Most patients reported chemotherapy and radiation side effects as their most challenging aspect of treatment.
Agenus (NASDAQ: AGEN) ha rilasciato i risultati del suo sondaggio nazionale "Colorectal Cancer in Focus", rivelando lacune critiche nelle attuali opzioni di trattamento. Il sondaggio, condotto da ottobre a dicembre 2024, ha raccolto informazioni da pazienti e operatori sanitari (HCP) riguardo alla cura del cancro colorettale (CRC).
I principali risultati mostrano che oltre il 50% degli HCP ha segnalato un aumento delle diagnosi di CRC negli adulti sotto i 50 anni, con l'82% dei pazienti intervistati diagnosticati prima di quell'età. Un impressionante 93% degli HCP crede che i trattamenti attuali per il CRC siano insufficienti. Il sondaggio ha evidenziato che il 61% dei pazienti ha espresso interesse per trattamenti non chemioterapici, inclusa l'immunoterapia, mentre il 37% degli HCP ha identificato l'immunoterapia come il progresso più promettente nel trattamento del CRC.
Lo studio, condotto in collaborazione con la Colorectal Cancer Alliance e Fight Colorectal Cancer, sottolinea la priorità dei pazienti per la qualità della vita, con un terzo che cita un impatto minimo sulla vita come una delle principali priorità di trattamento. La maggior parte dei pazienti ha segnalato gli effetti collaterali della chemioterapia e della radioterapia come il loro aspetto più impegnativo del trattamento.
Agenus (NASDAQ: AGEN) ha publicado los hallazgos de su encuesta nacional "Colorectal Cancer in Focus", revelando brechas críticas en las opciones de tratamiento actuales. La encuesta, realizada de octubre a diciembre de 2024, recopiló información de pacientes y proveedores de atención médica (HCP) sobre la atención del cáncer colorrectal (CRC).
Los hallazgos clave muestran que más del 50% de los HCP informaron un aumento en los diagnósticos de CRC en adultos menores de 50 años, con el 82% de los pacientes encuestados diagnosticados antes de esa edad. Un abrumador 93% de los HCP cree que los tratamientos actuales para el CRC son insuficientes. La encuesta destacó que el 61% de los pacientes expresó interés en tratamientos no quimioterapéuticos, incluida la inmunoterapia, mientras que el 37% de los HCP identificó la inmunoterapia como el avance más prometedor en el tratamiento del CRC.
El estudio, realizado en asociación con la Colorectal Cancer Alliance y Fight Colorectal Cancer, enfatiza la priorización de los pacientes por la calidad de vida, con un tercio citando un impacto mínimo en la vida como una de las principales prioridades de tratamiento. La mayoría de los pacientes informó que los efectos secundarios de la quimioterapia y la radioterapia eran su aspecto más desafiante del tratamiento.
Agenus (NASDAQ: AGEN)는 국가 대장암 포커스 조사 결과를 발표하며 현재 치료 옵션의 중요한 격차를 드러냈습니다. 이 조사는 2024년 10월부터 12월까지 진행되었으며, 대장암(CRC) 치료에 대한 환자와 의료 제공자(HCP)의 통찰력을 수집했습니다.
주요 결과는 50세 미만 성인에서 CRC 진단이 증가했다고 보고한 HCP가 50% 이상이며, 조사된 환자의 82%가 그 연령 이전에 진단받았다는 것을 보여줍니다. 압도적인 93%의 HCP는 현재 CRC 치료가 불충분하다고 믿고 있습니다. 조사에서는 61%의 환자가 면역 요법을 포함한 비화학 요법 치료에 대한 관심을 표현했으며, 37%의 HCP는 면역 요법을 CRC 치료에서 가장 유망한 발전으로 지목했습니다.
이 연구는 대장암 동맹 및 Fight Colorectal Cancer와 협력하여 수행되었으며, 환자들이 삶의 질을 우선시하고 있음을 강조합니다. 응답자의 3분의 1은 최소한의 삶의 영향이 가장 중요한 치료 우선 사항이라고 언급했습니다. 대부분의 환자는 화학 요법과 방사선 치료의 부작용이 치료에서 가장 어려운 측면이라고 보고했습니다.
Agenus (NASDAQ: AGEN) a publié les résultats de son enquête nationale "Colorectal Cancer in Focus", révélant des lacunes critiques dans les options de traitement actuelles. L'enquête, menée d'octobre à décembre 2024, a recueilli des informations auprès de patients et de professionnels de santé (HCP) sur les soins du cancer colorectal (CRC).
Les principaux résultats montrent que plus de 50 % des HCP ont signalé une augmentation des diagnostics de CRC chez les adultes de moins de 50 ans, avec 82 % des patients interrogés diagnostiqués avant cet âge. Un impressionnant 93 % des HCP estiment que les traitements actuels du CRC sont insuffisants. L'enquête a mis en évidence que 61 % des patients ont exprimé un intérêt pour des traitements non chimiothérapeutiques, y compris l'immunothérapie, tandis que 37 % des HCP ont identifié l'immunothérapie comme le progrès le plus prometteur dans le traitement du CRC.
L'étude, réalisée en partenariat avec la Colorectal Cancer Alliance et Fight Colorectal Cancer, souligne la priorité des patients pour la qualité de vie, un tiers citant un impact minimal sur la vie comme une priorité de traitement majeure. La plupart des patients ont signalé que les effets secondaires de la chimiothérapie et de la radiothérapie étaient leur aspect le plus difficile du traitement.
Agenus (NASDAQ: AGEN) hat die Ergebnisse seiner nationalen Umfrage "Colorectal Cancer in Focus" veröffentlicht, die kritische Lücken in den aktuellen Behandlungsoptionen aufzeigt. Die Umfrage, die von Oktober bis Dezember 2024 durchgeführt wurde, sammelte Erkenntnisse von Patienten und Gesundheitsdienstleistern (HCPs) zur Behandlung von kolorektalem Krebs (CRC).
Wichtige Ergebnisse zeigen, dass über 50% der HCPs von einem Anstieg der CRC-Diagnosen bei Erwachsenen unter 50 Jahren berichteten, wobei 82% der befragten Patienten vor diesem Alter diagnostiziert wurden. Überwältigende 93% der HCPs glauben, dass die aktuellen CRC-Behandlungen unzureichend sind. Die Umfrage hob hervor, dass 61% der Patienten Interesse an nicht-chemotherapeutischen Behandlungen, einschließlich Immuntherapie, äußerten, während 37% der HCPs die Immuntherapie als den vielversprechendsten Fortschritt in der CRC-Behandlung identifizierten.
Die Studie, die in Partnerschaft mit der Colorectal Cancer Alliance und Fight Colorectal Cancer durchgeführt wurde, betont die Priorität der Patienten für die Lebensqualität, wobei ein Drittel angibt, dass ein minimaler Einfluss auf das Leben eine der wichtigsten Behandlungsprioritäten ist. Die meisten Patienten berichteten, dass die Nebenwirkungen von Chemotherapie und Strahlentherapie den herausforderndsten Aspekt ihrer Behandlung darstellen.
- None.
- None.
- Patients and Healthcare Providers Alike Call for More Innovative, Less Toxic Treatment Options
- CRC Diagnoses Rise While Current Standards Fall Short
Colorectal cancer remains the second leading cause of cancer-related deaths worldwide and places an enormous burden on individuals, their families and loved ones, and the healthcare system alike.1 The Colorectal Cancer in Focus survey, conducted online in the
Key Survey Insights:
-
Early-Onset CRC is on the Rise: More than half of HCPs reported an increase in CRC diagnoses among adults under 50, with
82% of surveyed patients diagnosed before that age. -
Gaps in the Standard of Care: Nearly all surveyed HCPs (
93% ) believe current treatment options for CRC are insufficient, with chemotherapy remaining the dominant approach despite its debilitating side effects. -
Rising Patient Demand for Chemotherapy Alternatives: A majority of patients highly value the possibility of treatments that do not involve chemotherapy.
61% expressed interest in new treatment options outside of chemotherapy, including immunotherapy (IO). -
Growing Interest in Immunotherapies: While awareness of IO therapies remains low among patients,
37% of HCPs cited IO therapies as the most promising potential advancement in CRC treatment. - Patients Prioritize Quality of Life: In addition to extending life, approximately one in three patients identified minimal impact on quality of life as a top treatment priority. Majority cited side effects of chemotherapy and/or radiation as the most difficult aspect of their cancer journey.
Steven O’Day, MD, Chief Medical Officer at Agenus, emphasized the importance of these findings:
“This survey underscores the urgent need for transformative solutions in colorectal cancer treatment. Patients and healthcare providers alike are calling for more effective options that not only extend survival but also preserve quality of life. At Agenus, we are committed to advancing next-generation immuno-oncology therapies that have the potential to address these unmet needs and bring meaningful progress to the CRC community.”
Acknowledging Advocacy Groups for Their Partnership
Agenus extends its gratitude to the Colorectal Cancer Alliance and Fight Colorectal Cancer for their collaboration in disseminating the patient survey and amplifying the voices of those affected by CRC. Their partnership has been instrumental in uncovering these critical insights and driving advocacy for meaningful change.
“Patients facing colorectal cancer deserve treatment options that prioritize both survival and quality of life,” said Michael Sapienza, CEO of the Colorectal Cancer Alliance. “The survey findings highlight a clear need for new therapies that are targeted and minimize harsh side effects. We’re proud to partner on this effort to amplify patient voices and advocate for innovative solutions that can transform care.”
"This survey reinforces what patients have long been telling us—current colorectal cancer treatments are not enough,” said Anjee Davis, CEO of Fight Colorectal Cancer. “Too many are facing limited options, debilitating side effects, and a lack of awareness about emerging therapies. It is critical that we prioritize patient-centered innovation that not only extends survival but also improves quality of life.”
With these findings, Agenus reaffirms its commitment to developing and accelerating access to novel therapies that harness the power of the immune system. Through continued collaboration with researchers, advocacy organizations, and healthcare providers, the company aims to advance treatment innovation and improve the standard of care for CRC patients worldwide.
For more information about the Colorectal Cancer in Focus survey and Agenus’ efforts in CRC research, please visit https://agenusbio.com/colorectal-cancer-in-focus/.
1 |
Center for Disease Control and Prevention. Colorectal Cancer Basics. https://www.cdc.gov/colorectalcancer/about/index.html |
About the Survey
The Colorectal Cancer in Focus survey was conducted online in the
About Agenus
Agenus is a leading immuno-oncology company developing innovative cancer treatments. Founded in 1994, the company is committed to expanding the reach of cancer immunotherapy through novel antibody therapeutics, adoptive cell therapies (via MiNK Therapeutics), and adjuvants (via SaponiQx). With end-to-end development capabilities, including commercial and clinical cGMP manufacturing, research, and a global clinical operations footprint, Agenus is uniquely positioned to drive innovation in immuno-oncology.
Agenus is headquartered in
Forward-Looking Statement
This press release contains forward-looking statements pursuant to the safe harbor provisions of federal securities laws. These statements include references to Agenus' botensilimab and balstilimab programs, expected regulatory timelines, and other projections. Forward-looking statements are identifiable by words such as “may,” “believes,” “expects,” “anticipates,” “hopes,” “intends,” “plans,” “forecasts,” “estimates,” “will,” “potential,” and similar expressions.
These statements are subject to risks and uncertainties that may cause actual results to differ materially. Such risks include those detailed in Agenus' most recent Annual Report on Form 10-K (2023) and subsequent Quarterly Reports on Form 10-Q, filed with the Securities and Exchange Commission (SEC). Agenus cautions investors not to place undue reliance on forward-looking statements and undertakes no obligation to update them except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319897329/en/
Investor:
917-362-1370
investor@agenusbio.com
Media:
781-674-4422
communications@agenusbio.com
Source: Agenus Inc.
FAQ
What are the key findings of Agenus (AGEN) 2024 Colorectal Cancer survey?
How many healthcare providers believe current colorectal cancer treatments are inadequate according to AGEN's survey?
What percentage of patients in the Agenus survey were diagnosed with colorectal cancer before age 50?
What treatment alternatives are patients seeking according to the 2024 AGEN survey?
Which organizations partnered with Agenus (AGEN) for the Colorectal Cancer in Focus survey?
